Business
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025 Current epidemiology and treatment practices for pulmonary sarcoidosis in the U.S. based on real-world evidence SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present three posters for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2025 International Conference, which is scheduled to take place May 16 – 21, 2025, in San Francisco, CA. Preliminary details of the poster presentations appear below. The posters will be available on the aTyr website once presented. Title: EFZO-FIT, Largest Placebo-Controlled Trial in Pulmonary Sarcoidosis – Trial Design and Patient Characteristics Session: Repair My Broken LungsDate and Time: Monday, May 19, 2025 from 9:15AM – 4:15PM PT Location: Moscone Center, San Francisco, CA Title: Real-World Treatment Patterns Among Pulmonary Sarcoidosis Patients with Parenchymal Involvement in the USSession: The Inflamed Lung: Sarcoidosis and Autoimmune DiseaseDate and Time: Sunday, May 18, 2025 from 9:15AM – 4:15PM PT Location: Moscone Center, San Francisco, CA Title: Incidence, Prevalence, and Mortality of Pulmonary Sarcoidosis with Parenchymal Involvement in the USSession: Current Insights into Risk, Diagnosis, and Treatment of Occupational and Environmental Lung DiseasesDate and Time: Tuesday, May 20, 2025 from 9:15AM – 4:15PM PT Location: Moscone Center, San Francisco, CA About Efzofitimod Efzofitimod is a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. aTyr is currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ stud...